Tasly 2025 Annual Report: Net profit attributable to the parent company increased by 15.63%, and strategic integration with China Resources Sanjiu marks the beginning of a new chapter.

China Visitor Network Data
Tasly Pharmaceutical Group Co., Ltd. (600535) released its 2025 annual report. During the reporting period, the company achieved operating revenue of 8.236 billion yuan, with main business revenue in the pharmaceutical industry of 7.382 billion yuan, a year-on-year decrease of 2.54%, mainly due to price reductions from centralized procurement and industry decline in traditional Chinese medicine injections; net profit attributable to shareholders of the listed company was 1.105 billion yuan, a year-on-year increase of 15.63%, mainly benefiting from the rise in fair value of financial assets invested in.
The company officially became a member of China Resources Sanjiu in March 2025 and completed its first year of integration. The company has established a new vision of “innovation-driven, becoming a leading enterprise in China’s pharmaceutical market,” focusing on three core treatment areas: cardiovascular and metabolic, neurological/psychiatric, and digestive.
In terms of R&D, the company has built an open innovation system driven by “innovative traditional Chinese medicine and advanced therapeutic drugs,” with R&D investment of 845 million yuan in 2025. It has 31 innovative drugs in development, including recombinant human urokinase (Puyuke) for acute ischemic stroke, which was approved in September 2025.
In marketing, the company has established an integrated marketing system centered on academic-driven strategies to strengthen the market position of core products.
In production, the company continuously reduces costs and increases efficiency through intelligent manufacturing and lean management. The “Modern Chinese Medicine Full Industry Chain Collaborative Intelligent Factory” was recognized as a “Top-tier Intelligent Factory” by the Ministry of Industry and Information Technology.
The board of directors proposes a cash dividend of 1 yuan (tax included) for every 10 shares to all shareholders.
Looking ahead, the company plans to achieve double the industrial revenue by the end of 2030 through organic growth and external expansion, aiming to rank among the top Chinese pharmaceutical companies.